Retroviral Vectors: From Laboratory Tools to Molecular Medicines

Richard G. Vile, Anna Tuszynski, Simon Castleden

Research output: Contribution to journalReview articlepeer-review

53 Scopus citations


The majority of clinical trials for gene therapy currently employ retroviral-mediated gene delivery. This is because the life cycle of the retrovirus is well understood and can be effectively manipulated to generate vectors that can be efficiently and safely packaged. Here, we review the molecular technology behind the generation of recombinant retroviral vectors. We also highlight the problems associated with the use of these viruses as gene therapy vehicles and discuss future developments that will be necessary to maintain retroviral vectors at the forefront of gene transfer technology.

Original languageEnglish (US)
Pages (from-to)139-158
Number of pages20
JournalApplied Biochemistry and Biotechnology - Part B Molecular Biotechnology
Issue number2
StatePublished - 1996


  • Clinical trials
  • Gene therapy
  • Gene transfer
  • Retroviral vectors
  • Retroviruses

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biochemistry
  • Applied Microbiology and Biotechnology
  • Molecular Biology


Dive into the research topics of 'Retroviral Vectors: From Laboratory Tools to Molecular Medicines'. Together they form a unique fingerprint.

Cite this